Three Chinese Pharmaceutical Giants — China Resources, Sinopharm, and Guangzhou Pharma — Enter Fortune Global 500 in 2021

Today (August 2), the Fortune Plus APP released the latest *Fortune* Global 500 list simultaneously worldwide. Impacted by the COVID-19 pandemic, the total revenue of companies on this year's *Fortune* Global 500 list was approximately $31.7 trillion, down 5% from last year. The threshold for entry (minimum revenue) also fell from $25.4 billion to $24 billion. Meanwhile, corporate profits have plummeted. The combined net profit of all ranked companies this year totaled $1.6 trillion, a sharp 20% year-on-year decline, marking the largest drop since 2009.

Notably, a total of 19 pharmaceutical companies were included in the top 500 list, with China Resources, Johnson & Johnson, and China National Pharmaceutical Group Corporation ranking first, second, and third among pharmaceutical enterprises, respectively; their revenues reached USD 99,437.6 million, USD 82,584 million, and USD 77,278.2 million, respectively.

In addition, six pharmaceutical companies were newly added to the list this year, namely AstraZeneca, Boehringer Ingelheim (Germany), Guangzhou Pharmaceutical Group Co., Ltd., Amgen, Gilead Sciences, and Eli Lilly and Company (United States).

Additionally, the rankings of Bayer and Pfizer declined to varying degrees; Bayer dropped 13 places, while Pfizer fell by 66 places.

List and Details of the 19 Fortune Global 500 Pharmaceutical Companies

Notably, this year three Chinese pharmaceutical enterprises have made it onto the *Fortune* Global 500 list: China Resources Limited, China National Pharmaceutical Group Corporation, and Guangzhou Pharmaceutical Holdings Limited. Although the ranking data for China Resources Group incorporates statistics from its non-pharmaceutical operations, there is no doubt that both China Resources and Sinopharm have long been "behemoth"-level enterprises in China's pharmaceutical industry.

China Resources Group Ranks Among the World's Top 100

Both total profit and net profit achieved double-digit growth.

It is reported that this year, China Resources Group's ranking has risen once again to 69th, continuing its consecutive upward trajectory since the company first debuted on the *Fortune* Global 500 list in 2010. Amid the pervasive COVID-19 pandemic, China Resources delivered an exceptional performance throughout the extraordinary year of 2020, achieving double-digit growth in both total profit and net profit.

Screenshot of the Fortune China Official Website

China National Pharmaceutical Group Corporation Posts 8 Consecutive Gains!

Operating Revenue Surpasses the RMB 500 Billion Mark for the First Time

According to the official WeChat account of China National Pharmaceutical Group Corporation, the Group has been listed on the *Fortune* Global 500 for the ninth consecutive year this year. Since its debut on the list in 2013, its ranking has steadily climbed, rising by 337 places to date.

It is reported that in 2020, China National Pharmaceutical Group Corporation’s annual operating revenue exceeded the RMB 500 billion mark for the first time, with total profit surpassing the RMB 20 billion mark. Compared with the end of the 12th Five-Year Plan period, key indicators such as operating revenue, total profit, total assets, and owners’ equity have all doubled. The Group continues to maintain its leading position in the industry in terms of scale, profitability, and growth rate. Moving forward, China National Pharmaceutical Group Corporation will go all out to advance the in-depth implementation of its overall development strategy for the 14th Five-Year Plan period—an innovation-driven framework centered on the “Four Pillars and Eight Beams, Hundred Enterprises and Trillion-Yuan” initiative, encompassing the full life cycle, complete industry chain, and comprehensive ecosystem. The Group will stride forward on a new journey to build a world-class, globally competitive, comprehensive pharmaceutical and healthcare industry group!

Guangzhou Pharmaceutical Holdings Limited Newly Enters the List

Will Promote Traditional Chinese Medicine to Go Global

Additionally, Guangzhou Pharmaceutical Group is a newly listed company on today's ranking. According to its financial reports, the group's total revenue exceeded 150 billion yuan in 2020, making it the first Chinese enterprise to enter the Fortune Global 500 with traditional Chinese medicine as its core business. In the first quarter of this year, total revenue reached 41.582 billion yuan, a year-on-year increase of 18.60%, while total profit amounted to 2.215 billion yuan, up 30.70% year-on-year.

As China's largest pharmaceutical enterprise and the largest production base for Chinese patent medicines, Guangzhou Pharmaceutical Group's business spans the entire pharmaceutical industrial chain, including pharmaceutical manufacturing, pharmaceutical distribution, medical and healthcare services, and other sectors. Its traditional Chinese medicine (TCM) operations are particularly distinctive, featuring 12 brands officially recognized as "China Time-Honored Brands." Ten of these enterprises boast histories of over a century, collectively accounting for half of all time-honored brands in China's pharmaceutical industry.

Guangzhou Pharmaceutical Group stated that it will further promote the global expansion of Traditional Chinese Medicine (TCM), and over the next five years, it will strive to build a world-class biopharmaceutical and healthcare enterprise with distinctive industrial features and a strong cultural identity.

Information Source: Public information including Fortune Network, official corporate WeChat accounts, announcements, and other publicly available information.

Responsible Editor: Sanqi

Disclaimer: This article is compiled by Yaozhi and does not necessarily reflect the views of this platform. Should any issues regarding the content, copyright, or other matters arise, please contact us by leaving a message on this official account, and we will remove the content promptly.